Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
141.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 3.00 (2.143%)
Market Cap: £119.75m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Block listing Interim Review

7 Oct 2025 07:00

RNS Number : 2250C
Diaceutics PLC
07 October 2025
 

Diaceutics PLC

 

Block Listing Return

 

New York, Belfast and London, 7 October 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.

 

Name of applicant:

Diaceutics PLC

Name of scheme:

UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long-term incentive awards.

Period of return:

From:

7 April 2025

To:

6 October 2025

Balance under scheme from previous return:

1,351,968 Ordinary Shares of £0.002 each

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

N/A

Number of securities issued/allotted under schemes during period:

95,317 Ordinary Shares

 

Balance under scheme not yet issued/allotted at end of period

1,256,651 Ordinary Shares

Number and class of securities originally listed and the date of admission

1,500,000 Ordinary Shares on 6 October 2023

Total number of securities in issue at the end of the period

84,893,695 Ordinary Shares of £0.002 each

Name of contact:

Nick Roberts

Telephone number of contact:

As below

 

Enquiries: 

Diaceutics PLC 

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 

Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPKABQKBDDDKK
Date   Source Headline
17th Dec 202410:46 amRNSHolding(s) in Company
17th Dec 20247:00 amRNSDiaceutics Wins New $5.1m Contract
10th Dec 20243:14 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSAwarded UK Research Institute Grant Funding of £1m
3rd Dec 20242:24 pmRNSTotal Voting Rights
28th Nov 20247:00 amRNSExpansion of US Commercial Activities
5th Nov 20247:00 amRNSCapital Markets Webinar
4th Nov 20247:00 amRNSHolding(s) in Company
30th Oct 20242:58 pmRNSPDMR Shareholding/Share Incentive Plan
29th Oct 202410:27 amRNSBoard Change Update
25th Oct 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
24th Oct 202412:53 pmRNSCancellation of Share Premium Account
15th Oct 20247:00 amRNS-RDiaceutics Announces Key Leadership Appointment
7th Oct 20241:19 pmRNSHolding(s) in Company
7th Oct 20247:00 amRNSBlock Listing Return
2nd Oct 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20247:00 amRNSBoard Changes
17th Sep 20247:00 amRNSH1 2024 Results - Continued Performance & Growth
9th Sep 20247:00 amRNSNotice of Results & Presentations
2nd Sep 20247:00 amRNSAppointment of Nominated Adviser and Broker
30th Aug 20243:45 pmRNSPDMR Shareholding/Share Incentive Plan
27th Aug 20247:00 amRNSDiaceutics Launches Enhanced Rare-Disease Offering
19th Aug 20247:00 amRNSEnterprise Partnership and Launch of PMx
5th Aug 20247:00 amRNSPresenting at Canaccord Genuity Growth Conference
29th Jul 20246:09 pmRNSPDMR Shareholding/SIP and TVR
29th Jul 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
23rd Jul 20247:05 amRNSBoard Changes
23rd Jul 20247:00 amRNSRevenue growth of 24% in H1 with 55% now recurring
11th Jul 20247:00 amRNSSenior Management Appointments
1st Jul 20247:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
24th Jun 20241:15 pmRNSResult of AGM
6th Jun 20247:00 amRNSDiaceutics - Capital Markets Event
29th May 20248:00 amRNSNotice of AGM and Posting of Annual Report
28th May 20247:00 amRNSData to be Presented at 2024 ASCO Annual Meeting
24th May 20243:01 pmRNSPDMR Shareholding/SIP and Total Voting Rights
23rd May 20247:00 amRNSDirector / PDMR Shareholding
21st May 20247:00 amRNSRevenue growth of 22% & order book growth of 57%
16th May 20247:00 amRNSTwo New Enterprise-Wide Engagements
14th May 20247:00 amRNSDiaceutics - Capital Markets Event
1st May 20247:00 amRNSNotice of Results & Presentations
30th Apr 20247:00 amRNSPDMR Shareholding/SIP and TVR
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR
27th Feb 20247:00 amRNSExpanded lab network and data capabilities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.